Related Experiment Video
Updated: Dec 10, 2025
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
A public-private partnership for the express development of antiviral leads: a perspective view
1School of Systems Biology, George Mason University , Manassas, USA.
Introduction:
The COVID-19 pandemic raises the question of strategic readiness for emergent pathogens. The current case illustrates that the cost of inaction can be higher in the future. The perspective article proposes a dedicated, government-sponsored agency developing anti-viral leads against all potentially dangerous pathogen species.
Areas Covered:
The author explores the methods of computational drug screening and in-silico synthesis and proposes a specialized government-sponsored agency focusing on leads and functioning in collaboration with a network of labs, pharma, biotech firms, and academia, in order to test each lead against multiple viral species. The agency will employ artificial intelligence and machine learning tools to cut the costs further. The algorithms are expected to receive continuous feedback from the network of partners conducting the tests.
Expert Opinion:
The author proposes a bionic principle, emulating antibody response by producing a combinatorial diversity of high q uality generic antiviral leads, suitable for multiple potentially emerging species. The availability of multiple pre-tested agents and an even greater number of combinations would reduce the impact of the next outbreak. The methodologies developed in this effort are likely to find utility in the design of chronic disease therapeutics.
Insights
A new government agency should develop broad-spectrum antiviral drug leads to prepare for future pandemics. This proactive approach, using computational methods and AI, can reduce future costs and mitigate outbreak impacts.
Area of Science:
- Virology
- Drug Discovery
- Public Health Policy
Background:
- The COVID-19 pandemic highlighted critical gaps in strategic preparedness for emergent viral pathogens.
- The economic and societal costs of inaction against novel viruses are substantial and can escalate over time.
Purpose of the Study:
- To propose a novel framework for a dedicated, government-sponsored agency focused on developing antiviral leads against diverse potentially dangerous pathogen species.
- To outline a strategy for enhancing global pandemic readiness through proactive antiviral development.
Main Methods:
- Exploration of computational drug screening and in-silico synthesis methodologies.
- Proposal for a specialized agency collaborating with academic institutions, pharmaceutical companies, and biotech firms.
- Integration of artificial intelligence (AI) and machine learning (ML) for cost reduction and efficiency.
Main Results:
- A proposed "bionic principle" emulating antibody response to generate a diverse library of high-quality, generic antiviral leads.
- Antiviral leads designed to be effective against multiple viral species, enabling rapid response to emerging threats.
- Anticipated utility of developed methodologies in designing therapeutics for chronic diseases.
Conclusions:
- Establishing a proactive, government-funded agency is crucial for strategic readiness against emergent pathogens.
- A collaborative network leveraging AI and computational tools can accelerate the development of broad-spectrum antiviral agents.
- This initiative promises to reduce the impact of future outbreaks and offers potential applications in chronic disease treatment.
Related Concept Videos
01:26Drug Discovery: Overview
01:28Preclinical Development: Overview